Hyperion DeFi (NASDAQ:HYPD) Price Target Raised to $6.60 at Cantor Fitzgerald

Hyperion DeFi (NASDAQ:HYPD) had its target price raised by Cantor Fitzgerald from $4.00 to $6.60 in a note issued to investors on Wednesday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. Cantor Fitzgerald’s target price suggests a potential upside of 113.94% from the company’s current price.

Several other analysts have also commented on HYPD. Weiss Ratings raised Hyperion DeFi from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, June 24th. Zacks Research downgraded Hyperion DeFi from a “hold” rating to a “strong sell” rating in a report on Monday, March 30th. Finally, Chardan Capital lowered their price objective on Hyperion DeFi from $8.25 to $7.30 and set a “buy” rating on the stock in a research report on Monday, June 8th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. According to MarketBeat.com, Hyperion DeFi presently has an average rating of “Hold” and a consensus price target of $6.95.

Hyperion DeFi Stock Performance

Shares of NASDAQ HYPD traded down $0.06 during trading on Wednesday, reaching $3.08. 109,179 shares of the company traded hands, compared to its average volume of 481,194. The firm’s fifty day simple moving average is $3.53 and its 200 day simple moving average is $3.50. The stock has a market cap of $46.77 million, a P/E ratio of -0.31 and a beta of 2.47. Hyperion DeFi has a 12-month low of $2.49 and a 12-month high of $17.18. The company has a current ratio of 1.97, a quick ratio of 1.97 and a debt-to-equity ratio of 0.12.

Insider Activity at Hyperion DeFi

In other Hyperion DeFi news, insider Hyunsu Jung bought 7,000 shares of the company’s stock in a transaction dated Monday, June 1st. The shares were purchased at an average cost of $3.70 per share, for a total transaction of $25,900.00. Following the transaction, the insider directly owned 1,384,676 shares of the company’s stock, valued at approximately $5,123,301.20. The trade was a 0.51% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. 7.50% of the stock is owned by company insiders.

Hedge Funds Weigh In On Hyperion DeFi

Hedge funds have recently bought and sold shares of the business. State Street Corp acquired a new stake in Hyperion DeFi in the fourth quarter valued at approximately $92,000. Jane Street Group LLC purchased a new position in shares of Hyperion DeFi during the 4th quarter valued at approximately $493,000. Renaissance Technologies LLC acquired a new stake in Hyperion DeFi in the 4th quarter valued at $663,000. Focus Partners Advisor Solutions LLC acquired a new stake in Hyperion DeFi in the 4th quarter valued at $221,000. Finally, Geode Capital Management LLC purchased a new stake in Hyperion DeFi in the 4th quarter worth $214,000. Hedge funds and other institutional investors own 25.84% of the company’s stock.

About Hyperion DeFi

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.